SCHEMBL2369346

SCHEMBL2369346

CN(Cc1ccco1)c1ncnc2scc(-c3cccs3)c12

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.57
HPGD P15428 3/20 0.57
LMNA P02545 12/20 0.46
CYP1A2 P05177 11/20 0.46
CYP3A4 P08684 11/20 0.46
CYP2C19 P33261 11/20 0.46
CYP2D6 P10635 10/20 0.46
ALDH1A1 P00352 8/20 0.46
HSD17B10 Q99714 7/20 0.46
MEN1 O00255 4/20 0.46
KMT2A Q03164 4/20 0.46
ALOX15 P16050 3/20 0.46
HTT P42858 5/20 0.46
NPSR1 Q6W5P4 2/20 0.46
SMN1; SMN2 Q16637 4/20 0.45
KDM4E B2RXH2 2/20 0.44
TDP1 Q9NUW8 2/20 0.44
TSHR P16473 10/20 0.43
CLK4 Q9HAZ1 6/20 0.43
USP2 O75604 5/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3388479 0.85 LMNA (0.60) MAPTHPGDLMNACYP1A2CYP3A4
SCHEMBL3382534 0.81 HTT (0.48) MAPTHPGDLMNAALDH1A1HSD17B10
SCHEMBL3387876 0.77 HTT (0.47) MAPTHPGDLMNAALDH1A1HSD17B10
SCHEMBL3382531 0.76 SMN1; SMN2 (0.65) MAPTHPGDLMNACYP1A2CYP3A4
SCHEMBL3385129 0.73 SMN1; SMN2 (0.48) MAPTHPGDLMNAALDH1A1HSD17B10
SCHEMBL16281238 0.70 KDM4E (0.56) MAPTHPGDLMNAALDH1A1HSD17B10
SCHEMBL5327351 0.68 CHEK1 (0.47) MAPTHPGDLMNACYP1A2CYP2C19
SCHEMBL14090790 0.68 ALDH1A1 (0.54) MAPTHPGDLMNACYP1A2CYP2C19
Hydrochloric Acid SCHEMBL5321501 0.67 CHEK1 (0.46) MAPTHPGDLMNACYP1A2CYP2C19
SCHEMBL14414209 0.67 MAP4K4 (0.63) MAPTHPGDLMNACYP1A2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8022076-B2 Thieno[2,3-d]pyrimidine derivatives as potassium channel modulators; antiarrhythmia agents XENTION LIMITED (GB) 2011-09-20 US disclosed
EP-1641803-B3 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS XENTION LTD (GB) 2010-12-08 EP disclosed
EP-1641803-B1 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS XENTION LTD (GB) 2009-03-18 EP disclosed
EP-1641803-A1 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS Xention Discovery Limited (GB) 2006-04-05 EP disclosed
US-20050026935-A1 Compounds XENTION DISCOVERY LTD. 2005-02-03 US disclosed
WO-2004111057-A1 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS XENTION DISCOVERY LIMITED (GB) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050026935-A1 Compounds KCNJ11, KCNJ1, KCNH1 MAPT 2978/4885HPGD 1231/4885LMNA 1126/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.